ClinicalTrials.gg
Not yet recruitingNCT07831577RAPHAELUpdated Sep 21, 2026

Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

A Phase 2/3 interventional study of Gene Therapy GNSC-001 and Placebo in Knee Arthritis Osteoarthritis, Knee Arthritis, Osteoarthritis and Knee Arthritis, sponsored by Genascence Corporation. Not yet recruiting. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Genascence Corporation · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if GNSC-001 works to treat knee osteoarthritis in adults. It will also learn about the safety of GNSC-001. The main questions it aims to answer are:

  1. Does GNSC-001 lower daily knee joint pain and improve function in participants?
  2. What medical problems do participants have when taking GNSC-001?

Researchers will compare GNSC-001 to a placebo (a look-alike substance that contains no drug) to see if GNSC-001 works to treat knee osteoarthritis.

Participants will:

  1. Receive a single injection of immune-modulation, and GNSC-001 or a placebo, in their knee
  2. Take an oral immune-modulating pill every day for the first 22 days
  3. Visit the clinic at least 9 times over 2 years for checkups and tests
  4. Keep a diary of their symptoms and the number of times they use a rescue medication
02

Conditions studied

  • Knee Arthritis Osteoarthritis
  • Knee Arthritis, Osteoarthritis
  • Knee Arthritis
  • Knee Arthritis Disease
  • Osteo Arthritis of the Knee
  • Osteoarthritic Knee Pain
  • Osteoarthritis (OA) of the Knee
  • Osteo Arthritis Knee
  • Pain (Knee)

Keywords

  • Adeno-associated virus
  • Gene therapy
  • Intra-articular
  • GNSC-001
  • Genascence
  • Knee pain
  • Knee arthritis
  • Osteoarthritis
03

In context

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

This study's planned enrollment of 240 is above the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Genascence Corporation is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • OA in the target knee confirmed by radiograph and with a Kellgren-Lawrence (KL) score of 2 or 3
  • OA symptoms affecting the target knee present for at least 6 months
  • NRS pain score 5-9 (0-10 scale) in the target knee within the 24 hours prior to the time of consent
  • Synovitis and/or effusion detectable on imaging
  • Willing to stop use of any medication taken for knee OA pain for the duration of the study, including but not limited to nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Able to provide written and comply with the requirements of the study

Key Exclusion Criteria:

  • (BMI) > 38 kg/m2
  • NRS pain score in other (non-target) knee ≥ 4
  • Large effusion, substantial malalignment, structural compromise, prior partial or total joint replacement of target knee
  • Surgery on the target knee within the 6 months prior to screening or the anticipated need for treatment of either knee prior to the Month 12 Visit.
  • Current or history of inflammatory conditions (e.g., gout or rheumatoid arthritis), other joint disorders, septic arthritis, nerve damage or injury, chronic pain not associated with knee OA (e.g., fibromyalgia, hip OA), or otherwise
  • Active infection
  • Uncontrolled diabetes mellitus, glycosylated () >7.0% at screening
  • Initiation of GLP-1RA, or similar medication, within the last 12 months, or discontinued within last 6 months prior to Screening
  • Use of opioid medications (including tramadol or tapentadol) or medical/recreational cannabinoids (oral/inhaled) for > 5 days within the last 30 days
  • Use of medications for the treatment of chronic pain, immunosuppressant medications, or intra-articular injections into the target knee within 90 days of Day 1
  • Current use of anticoagulant therapy
  • Received within 6 weeks of Day 1
  • Participation in another interventional clinical study with experimental therapy within 90 days prior to screening
  • Relies on a walking aids (e.g., cane, crutch, walker, wheelchair) or a personal assistant
  • Pregnant, breastfeeding, or intending to become pregnant during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    GNSC-001

    Drug: Gene Therapy GNSC-001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugGene Therapy GNSC-001

    Single intra-articular injection into target knee

  • DrugPlacebo

    Single intra-articular injection into target knee

06

What researchers measure

Primary outcomes

  1. Change from baseline in OA pain as assessed by the Weekly Average of Daily Pain (WADP) Numeric Rating Scale (NRS) at Week 52

    Time frame: Baseline and Week 52

  2. Change from baseline in the function subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Week 52

    Time frame: Baseline and Week 52

  3. Incidence and severity of treatment emergent adverse events (TEAEs), events of clinical interest (ECIs), and serious adverse events (SAEs)

    Time frame: From enrollment to the end of study at 104 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2027; primary completion for Oct 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 21, 2026
StartEst.
Jul 2027
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2030
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07831577
Lead sponsor
Genascence Corporation
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Jul 2027 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2030 (estimated)
Last update
Sep 21, 2026

Study contacts

Head of Clinical Development
Contact
inquiries@genascence.com
408-475-8627

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion